OverviewSuggest Edit

CHIOME Bioscience is a company that researches and develops a drug discovery technology platform. It provides the ADLib system, a monoclonal antibody generating technology for drug discovery and development. Besides, the company delivers protein expression and purification services as well as stable cell line generation for recombinant protein and antibody production.
TypePublic
Founded2005
Websitechiome.co.jp

Latest Updates

Employees (est.) (Dec 2019)53
Share Price (Oct 2020)¥226 (+2%)
Cybersecurity ratingAMore

CHIOME Bioscience Financials and Metrics

CHIOME Bioscience Revenue

Market capitalization (23-Oct-2020)

8.3b

Closing stock price (23-Oct-2020)

226.0
CHIOME Bioscience's current market capitalization is ¥8.3 b.
Show all financial metrics

CHIOME Bioscience Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

CHIOME Bioscience Online and Social Media Presence

Embed Graph

CHIOME Bioscience Frequently Asked Questions

  • When was CHIOME Bioscience founded?

    CHIOME Bioscience was founded in 2005.

  • How many employees does CHIOME Bioscience have?

    CHIOME Bioscience has 53 employees.

  • Who are CHIOME Bioscience competitors?

    Competitors of CHIOME Bioscience include Gotham Therapeutics, Pepscan and Tango Therapeutics.